HTBX - ヒ―ト・バイオロジクス (Heat Biologics Inc.) ヒ―ト・バイオロジクス

 HTBXのチャート


 HTBXの企業情報

symbol HTBx
会社名 Heat Biologics Inc (ヒ―ト・バイオロジクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ヒート・バイオロジクス(Heat Biologics Inc.)は開発段階のバイオ医薬品会社であり、多様な癌と感染性疾患に有効な同種異系、既製の細胞治療ワクチンの開発に従事する。同社のImmunePan抗原細胞傷害性療法(インパクト)は癌患者の免疫系を活性化して癌性細胞を認識して殺させる一連の癌関連抗原及び「gp96」と呼ばれる免疫アジュバントを送り出すように再プログラムされた遺伝子組換えの被照射ヒト生細胞を送達するために設計されている。同社の主要な製品候補は、「HS-110」と「HS-410」である。同社はまた乳癌と卵巣癌向けの「ImPACT」という治療用ワクチンを開発している。   ヒ―ト・バイオロジクスは開発段階の米国のバイオ医薬品会社。がんや感染症に対応するアロジェニック、およびオフザシェルフ細胞療法ワクチンの開発に注力する。新薬候補には非小細胞性肺がん治療用のHS-110、および膀胱がん治療用のHS-410がある。本社はノ―スカロライナ州。   Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
本社所在地 801 Capitola Drive Durham NC 27713 USA
代表者氏名 Jeffrey Alan Wolf ジェフリー・アラン・ウルフ
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 919-240-7133
設立年月日 39600
市場名 NASDAQ Small Cap
ipoyear 2013年
従業員数 19人
url www.heatbio.com
nasdaq_url https://www.nasdaq.com/symbol/htbx
adr_tso
EBITDA EBITDA(百万ドル) -14.67771
終値(lastsale) 1.88
時価総額(marketcap) 43479293.92
時価総額 時価総額(百万ドル) 40.01020
売上高 売上高(百万ドル) 2.98016
企業価値(EV) 企業価値(EV)(百万ドル) 15.34947
当期純利益 当期純利益(百万ドル) -21.03366
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Heat Biologics Inc revenues increased from $435K to $1.9M. Net loss increased 18% to $7.6M. Revenues reflect Grant and licensing revenue increase from $411K to $1.9M. Higher net loss reflects Research and Development increase of 60% to $6.4M (expense) General and administrative increase of 1% to $3.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$1.02.

 HTBXのテクニカル分析


 HTBXのニュース

   Traders cant mares this Stock: Ford Motor Company (NYSE:F), Heat Biologics, Inc. (NASDAQ:HTBX)  2021/07/08 02:19:56 Stock Equity
Ford Motor Company (NYSE:F) with the stream of -1.17% also noticed, India Heat Biologics, Inc. (NASDAQ:HTBX) encountered a rapid change of -3.24% in the last hour of Wednesdays trading session. The post Traders cant mares this Stock: Ford Motor Company (NYSE:F), Heat Biologics, Inc. (NASDAQ:HTBX) appeared first on Stocks Equity .
   Traders should take notice on: CommScope Holding Company, Inc. (NASDAQ:COMM), Heat Biologics, Inc. (NASDAQ:HTBX)  2021/06/28 23:32:34 Stock Equity
CommScope Holding Company, Inc. (NASDAQ:COMM) with the stream of -0.42% also noticed, India Heat Biologics, Inc. (NASDAQ:HTBX) encountered a rapid change of -1.52% in the last hour of MONDAYs trading The post Traders should take notice on: CommScope Holding Company, Inc. (NASDAQ:COMM), Heat Biologics, Inc. (NASDAQ:HTBX) appeared first on Stocks Equity .
   Heat Biologics added to Russell Microcap Index  2021/06/28 12:11:09 Seeking Alpha
   Heat Biologics Joins Russell Microcap Index  2021/06/28 11:30:00 Wallstreet:Online
DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has been added to the Russell Microcap Index, following the annual Russell indexes reconstitution, effective after the US market opens today, June 28, 2021, according
   Morrisvilles Heat Biologics doubles R&D facilities  2021/06/23 23:09:54 Business Journals
(Triangle Business Journal)
   Morrisvilles Heat Biologics doubles R&D facilities  2021/06/23 23:09:54 Business Journals
(Triangle Business Journal)
   Heat Biologics expands R&D and pre-clinical capabilities  2021/06/23 11:48:38 Seeking Alpha
   Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters  2021/06/23 11:30:00 Heat Biologics
   Hot Stocks Alert- Heat Biologics, Inc. (NASDAQ:HTBX) encountered the change of 2.13%  2021/06/20 22:12:57 Stock Equity
On Friday, Shares of Heat Biologics, Inc. (NASDAQ:HTBX) reached at $7.20 price level during last trade its distance from 20 days simple moving average was 5.13%, and its distance from The post Hot Stocks Alert- Heat Biologics, Inc. (NASDAQ:HTBX) encountered the change of 2.13% appeared first on Stocks Equity .
   Remarkable Stock in Focus: Heat Biologics, Inc. (NASDAQ:HTBX), AIM ImmunoTech Inc. (AMEX:AIM)  2021/06/17 23:45:51 Stock Equity
Heat Biologics, Inc. (HTBX) with the stream of -0.64% also noticed, India AIM ImmunoTech Inc. (AIM) encountered a rapid change of 0.46% in the last hour of Thursdays trading session. The post Remarkable Stock in Focus: Heat Biologics, Inc. (NASDAQ:HTBX), AIM ImmunoTech Inc. (AMEX:AIM) appeared first on Stocks Equity .
   Remarkable Stock in Focus: Heat Biologics, Inc. (NASDAQ:HTBX), AIM ImmunoTech Inc. (AMEX:AIM)  2021/06/17 23:45:51 Stock Equity
Heat Biologics, Inc. (HTBX) with the stream of -0.64% also noticed, India AIM ImmunoTech Inc. (AIM) encountered a rapid change of 0.46% in the last hour of Thursdays trading session. The post Remarkable Stock in Focus: Heat Biologics, Inc. (NASDAQ:HTBX), AIM ImmunoTech Inc. (AMEX:AIM) appeared first on Stocks Equity .
   Small Cap Alert: Heat Biologics, Inc. (NASDAQ:HTBX), Kohls Corporation (NYSE:KSS)  2021/06/15 22:22:52 Stock Equity
Heat Biologics, Inc. (NASDAQ:HTBX) with the stream of -4.48% also noticed, India Kohls Corporation (NYSE:KSS) encountered a rapid change of 0.68% in the last hour of Tuesdays trading session. Heat The post Small Cap Alert: Heat Biologics, Inc. (NASDAQ:HTBX), Kohls Corporation (NYSE:KSS) appeared first on Stocks Equity .
   Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting  2021/06/04 00:00:00 BioSpace
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients
   Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting  2021/05/20 11:30:00 Heat Biologics
   Heat Biologics Inc (HTBX) falls 2.66% for May 19  2021/05/19 22:00:17 Equities
Heat Biologics Inc (NASDAQ: HTBX) shares fell -2.66% to end trading Wednesday at $6.23 per share - a net change of $-0.17. Shares traded between $6.32 and $6.03 throughout the day. 246015 shares of Heat Biologics Inc exchanged hands. Visit Heat Biologics Incs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Heat Biologics Inc and to follow the companys latest updates, you can visit the companys profile page here: Heat Biologics Incs Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ヒ―ト・バイオロジクス HTBX Heat Biologics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)